溶瘤痘苗病毒：一种很有前途的癌症治疗药剂  

Oncolytic vaccinia virus： a promising agent for cancer treatment

作　　者：马茜[1] 柴长斌[1] 何星辰[1] 党阳[1] 常侨 汪洋[1] 

机构地区：[1]西安医学院基础医学部,710021

出　　处：《中华微生物学和免疫学杂志》2016年第10期795-800,共6页Chinese Journal of Microbiology and Immunology

基　　金：国家自然科学基金（30972803）;陕西省科技统筹创新工程计划项目（2016KTCQ03-07）

摘　　要：痘苗病毒因其在人类消灭天花中的广泛应用，以及天然具有选择性感染肿瘤细胞并在其内复制进而裂解肿瘤细胞而不影响正常组织的特性，成为一种很有前途的肿瘤治疗生物制品。近些年，有很多策略被成功用于改造痘苗病毒以提高病毒的肿瘤选择性和抗肿瘤活性。到目前，这种经改造的痘苗病毒如JX-594在治疗癌症上取得了可喜的成果，且在临床试验中进展迅速。本文首先简要介绍痘苗病毒，然后重点综述溶瘤痘苗病毒的改造策略和临床试验的最新进展情况，最后还将探讨痘苗病毒作为溶瘤药物面临的主要挑战和未来发展方向。Vaccinia virus （VACV） has been widely used in humans for the eradication of small- pox. Since its natural ability of selective infection and replication in tumor cells without harming the normal tissue, VACV becomes a promising candidate in cancer therapy. In recent years, a variety of strategies have been successfully applied to further enhance the tumor selectivity and anti-tumor efficacy of VACV. These engineered VACVs, such as JX-594, have shown promising results in cancer treatment and have made re- markable progress in clinical trials. This review first briefly introduces the oncolytic VACV, and then focuses on the strategies applied in VACV engineering. We also discuss the main challenges and the future directions in the develooment of oncolytic VACV.

关 键 词：痘苗病毒 溶瘤病毒 修饰策略 肿瘤治疗 临床试验 

分 类 号：R730.5[医药卫生—肿瘤]